famili
immun
respons
b
r
c
onchocerca
volvulu
activationassoci
secret
good
adjuvant
varieti
antigen
vaccin
probabl
due
abil
activ
antigenprocess
cell
apc
howev
function
domain
adjuv
clearli
defin
base
structur
predict
protein
famili
construct
recombin
protein
contain
core
domain
residu
design
asppr
found
asppr
exhibit
adjuvant
similar
fulllength
residu
variou
antigen
includ
ovalbumin
ova
hbsag
protein
antigen
hiv
peptid
antigen
suitabl
vaccin
design
aspprantigen
fusion
protein
stabl
pb
store
c
result
suggest
asppr
might
function
region
adjuv
therefor
could
develop
adjuv
human
use
vaccin
effect
econom
strategi
prevent
treat
varieti
infect
recent
year
develop
proteinor
peptidebas
subunit
vaccin
becom
great
interest
due
improv
safeti
howev
typic
elicit
weak
modest
antibodi
respons
littl
cell
respons
thu
adjuv
ad
formul
improv
efficaci
new
gener
subunit
vaccin
adjuv
current
licens
human
vaccin
us
andor
europ
includ
aluminum
alum
salt
oilinwat
emuls
virosom
monophosphoryl
lipid
mpl
alum
salt
wide
use
adjuv
alum
induc
good
antibodi
respons
littl
capac
stimul
strong
cellular
immun
respons
effect
peptid
antigen
oilinwat
emuls
adjuv
well
use
vaccin
formul
influenza
viru
hpv
hbv
respect
abl
permit
dose
reduct
induc
longer
durat
antibodi
respons
could
enhanc
immunogen
peptid
antigen
adjuv
recent
undergon
increas
scrutini
advers
reaction
includ
increas
risk
narcolepsi
induc
children
adolesc
young
peopl
accordingli
new
gener
adjuv
capabl
safe
induc
humor
cellular
immun
respons
proper
magnitud
breadth
potenc
need
vaccin
develop
futur
subunit
vaccin
immunostimulatori
adjuv
direct
activ
innat
immun
receptor
tolllik
receptor
tlr
nodlik
receptor
nlr
ctype
lectin
receptor
clr
rigilik
receptor
rlr
cytosol
dna
sensor
endoplasm
reticulum
er
resid
transmembran
protein
stimul
ifn
gene
sting
innat
adjuv
includ
ligand
mpl
ligand
poli
c
ligand
flagellin
cpg
odn
apart
immunostimulatori
molecul
sever
helminthprotein
report
adjuv
effect
use
differ
vaccin
model
howev
induc
immun
respons
previou
studi
shown
protein
name
activationassoci
secret
onchocerca
volvulu
potent
adjuv
variou
vaccin
antigen
includ
synthet
peptidebas
antigen
importantli
formul
vaccin
antigen
either
aqueou
admixtur
fusion
protein
attribut
adjuv
includ
easi
formul
ii
enabl
reduct
dosag
vaccin
antigen
iii
capac
acceler
enhanc
antibodi
respons
target
vaccin
antigen
iv
abl
elicit
mix
antibodi
respons
cellular
immun
respons
antigen
v
elicit
balanc
immun
respons
variou
vaccin
vi
augment
recal
respons
vaccin
antigen
shown
bind
specif
human
antigen
present
cell
apc
trigger
proinflammatori
cytokin
product
pbmc
like
abil
activ
monocytederiv
dendrit
cell
howev
function
region
adjuv
yet
defin
studi
found
truncat
fragment
residu
kda
contain
core
domain
design
asppr
exhibit
adjuvant
similar
fulllength
residu
analyz
structur
pathogenesisrel
famili
protein
particular
crystal
structur
homologu
protein
deriv
parasit
nematod
necat
americanu
use
swissmodel
workspac
program
predict
domain
identifi
accordingli
truncat
fragment
asppr
contain
residu
design
e
coli
codonoptim
cdna
synthes
insert
express
vector
pqeasppr
recombin
construct
express
e
coli
previous
describ
asppr
express
analyz
sdspage
confirm
western
blot
use
monoclon
antibodi
mab
prepar
laboratori
asppr
purifi
ninta
chromatographi
previous
describ
modif
major
differ
condit
purif
recombin
protein
dialyz
end
pb
wherea
previous
protein
stop
laemmli
buffer
mm
tri
mm
glycin
sd
ph
briefli
inclus
bodi
contain
target
recombin
protein
dissolv
urea
overnight
c
solubl
denatur
protein
purifi
nief
genscript
use
denatur
condit
subsequ
refold
gradient
dialysi
urea
trisglycin
buffer
follow
laemmli
buffer
pb
h
step
purifi
protein
pass
lipopolysaccharid
lp
remov
gel
detoxigel
tm
pierc
biotechnolog
rockford
il
remov
contamin
lp
analyz
sdspage
fulllength
prepar
use
protocol
final
recombin
asppr
protein
use
follow
experi
neg
bacteri
endotoxin
determin
limulu
amebocyt
lysat
lal
assay
purifi
asppr
control
endotoxinfre
pb
aliquot
steril
tube
store
c
freezer
protein
concentr
sampl
taken
month
respect
frozen
measur
bradford
assay
calcul
accord
standard
curv
splenocyt
femal
balbc
mice
isol
count
cell
incub
purifi
asppr
final
concentr
gml
room
temperatur
min
follow
incub
antibodi
cocktail
bd
bioscienc
fitcantihi
dilut
miltenyi
biotec
inc
antibodi
anoth
min
stain
cell
collect
flow
cytometri
bd
facscalibur
tm
bd
bioscienc
analyz
use
flowjo
adjuvant
asppr
evalu
balbc
mice
use
two
protein
ova
hbsag
one
peptid
identifi
thepitop
rich
region
locat
pkvsfepipihycapagfailkcnnktfn
model
vaccin
antigen
six
femal
balbc
mice
per
group
intramuscularli
administr
ova
g
hbsag
g
g
endotoxinfre
pb
gibco
formul
asppr
g
alum
invivogen
ratio
alum
antigen
boost
antigen
adjuv
later
either
antigen
alon
endotoxinfre
pb
gibco
use
control
mous
sera
collect
immun
week
final
immun
detect
specif
antibodi
splenocyt
isol
third
week
boost
evalu
cellular
immun
respons
elisa
use
measur
serum
igg
antibodi
antigen
mice
vaccin
three
test
antigen
ovalbumin
ova
hbsag
plu
respect
adjuv
describ
use
protocol
similar
describ
previous
ova
hbsag
hiv
asppr
final
concentr
gml
use
captur
antigen
elisa
specif
splenocyt
vaccin
mice
measur
mous
elispot
accord
manufactur
recommend
bd
bioscienc
briefli
splenocyt
cellswel
incub
h
without
peptid
antigen
hbsag
ipqsldswwtsl
pkvsfepipihycapagf
final
concentr
gml
spot
count
elispot
reader
ctl
express
number
spotform
cell
sfc
cell
statist
analys
perform
use
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
oneway
analysi
varianc
avova
use
comparison
mean
geometr
mean
multipl
group
pvalu
less
consid
statist
signific
asppr
fragment
residu
contain
core
domain
express
e
coli
similar
asppr
express
mainli
form
inclus
bodi
recombin
asppr
nativ
form
obtain
purif
refold
gradient
dialysi
pb
fig
recogn
mab
detect
western
blot
fig
indic
asppr
success
express
e
coli
notic
asppr
pb
store
c
month
stabl
kept
condit
fig
supplementari
materi
relat
articl
found
onlin
version
http
determin
whether
truncat
asppr
fragment
would
function
manner
similar
first
compar
bind
profil
asppr
splenocyt
healthi
balbc
mice
use
fitclabel
antihi
antibodi
recogn
histag
nterminu
asppr
asppr
share
similar
bind
profil
asppr
demonstr
higher
bind
abil
b
nk
cell
well
macrophag
within
splenocyt
fig
suggest
asppr
might
function
core
first
compar
adjuvant
asppr
alum
use
ova
model
antigen
frequent
use
evalu
adjuvant
similar
alum
result
show
asppr
significantli
augment
igg
antibodi
respons
ova
vs
ova
alon
p
fig
comparison
igg
subtyp
reveal
antibodi
similarli
augment
presenc
asppr
alum
fig
antibodi
respons
elicit
asppr
vaccin
group
p
fig
c
result
indic
asppr
abl
elicit
mix
respons
differ
skew
respons
induc
alum
suggest
asppr
abil
maintain
balanc
adjuvant
elicit
observ
adjuv
effect
asppr
recombin
vaccin
protein
use
recombin
protein
hbsag
protect
antigen
hepat
b
viru
presenc
asppr
immun
mice
asppr
augment
igg
antibodi
respons
fig
also
increas
fig
fig
c
antibodi
respons
reflect
bioactiv
profil
much
differ
alum
note
asppr
induc
significantli
higher
antibodi
respons
p
similar
level
antibodi
igg
elispot
assay
reveal
asppr
well
elicit
higher
product
hbsag
peptidespecif
fig
asppr
also
induc
higher
fig
respons
wherea
alum
stimul
significantli
higher
taken
togeth
result
indic
asppr
augment
protein
antigeninduc
antibodi
respons
also
enhanc
specif
cellular
immun
respons
suggest
asppr
retain
adjuvant
recombin
protein
antigen
hbsag
test
whether
asppr
would
act
effect
adjuv
synthet
peptid
use
peptid
model
vaccin
peptid
elisa
result
reveal
asppr
augment
humor
cellular
immun
respons
similar
stimul
significantli
higher
igg
fig
fig
fig
c
antibodi
respons
alum
elispot
result
show
asppr
augment
product
fig
alum
induc
signific
fig
respons
immun
mice
find
demonstr
asppr
similar
effect
adjuv
also
select
peptid
antigen
peptid
adjuv
proven
import
compon
vaccin
make
essenti
explor
identifi
novel
adjuv
suitabl
variou
type
vaccin
antigen
particular
safe
nontox
adjuv
abl
stimul
humor
cellular
immun
respons
differ
type
antigen
sought
previou
studi
shown
aqueou
formul
bystand
antigen
effici
adjuv
sever
vaccin
antigen
includ
recombin
protein
synthet
peptid
commerci
inactiv
vaccin
moreov
induc
mix
respons
antibodi
profil
mani
antigen
howev
function
region
still
unknown
studi
show
asppr
might
function
fragment
retain
potent
adjuvant
demonstr
full
length
asppr
stabl
pb
genealog
tree
analysi
sequenc
reveal
belong
cap
superfamili
also
includ
align
amino
fig
bioactiv
truncat
fragment
asppr
vitro
splenocyt
healthi
balbc
mice
isol
analyz
bioactiv
asspr
purifi
asppr
final
concentr
gml
ad
naiv
mous
splenocyt
ml
round
bottom
tube
incub
room
temperatur
min
follow
incub
antibodi
cocktail
fitcantihi
antibodi
dilut
anoth
min
stain
cell
analyz
flow
cytometri
overlay
analysi
done
flowjo
gray
shade
stand
blank
control
blue
line
hisfitc
control
red
line
asppr
hisfitc
present
data
repres
result
three
mice
interpret
refer
color
figur
legend
reader
refer
web
version
articl
acid
sequenc
show
major
conserv
domain
form
similar
tertiari
structur
publish
use
crystal
structur
model
design
potenti
function
fragment
asppr
correspond
structur
conserv
domain
success
express
e
coli
system
investig
reveal
asppr
retain
cell
bind
profil
higher
bind
capac
demonstr
abil
bind
mous
b
nk
cell
well
macrophag
previous
shown
bind
mostli
human
b
cell
monocyt
previous
shown
fulllength
enhanc
humor
cellular
immun
respons
protein
antigen
result
prove
asppr
retain
adjuvant
common
use
model
antigen
ova
test
adjuvant
asppr
use
hbsag
import
protect
antigen
hbv
key
compon
hbv
vaccin
immun
hbsag
use
alum
induc
antibodi
respons
benefici
hbv
clearanc
expect
asppr
effect
augment
balanc
humor
cellular
immun
respons
hbv
indic
asppr
retain
adjuvant
adjuv
recombin
protein
peptidebas
subunit
vaccin
advantag
eas
design
modif
product
howev
rel
low
immunogen
formul
adjuv
enhanc
immunogen
thu
far
licens
adjuv
human
use
alum
effect
enhanc
peptideinduc
immun
respons
new
adjuv
poli
c
agonist
proven
effect
peptid
antigen
induc
advers
effect
may
limit
applic
previou
studi
show
effici
adjuv
also
sar
hiv
peptid
antigen
aqueou
influenza
peptid
recombin
fusion
protein
form
link
influenza
present
studi
demonstr
truncat
asppr
fig
antiova
antibodi
balbc
mice
immun
asppr
ova
sixweekold
femal
balbc
mice
immun
intramuscularli
g
endotoxinfre
ova
g
recombin
asppr
boost
week
later
mice
immun
ova
ova
alum
ova
alon
pb
control
serum
collect
third
week
final
immun
antiovaspecif
antibodi
includ
igg
b
c
measur
elisa
data
present
geometr
mean
sd
fig
antihbsag
antibodi
cellular
immun
respons
balbc
mice
immun
asppr
hbsag
balbc
mice
intramuscularli
immun
g
recombin
hbsag
g
recombin
asppr
boost
week
later
mice
immun
hbsag
plu
hbsag
plu
alum
hbsag
alon
pb
alon
use
control
upper
antibodi
level
mous
sera
sera
collect
third
week
final
immun
antihbsagspecif
antibodi
igg
fig
fig
fig
measur
elisa
antibodi
titer
express
geometr
mean
sd
lower
elispot
assay
splenocyt
immun
mice
isol
stimul
gml
peptid
specif
hbsag
observ
specif
cellular
immun
respons
count
spot
plate
fig
fig
repres
data
one
six
mice
present
fig
fig
fig
measur
elisa
express
geometr
mean
sd
lower
panel
elispot
assay
splenocyt
immun
mice
isol
stimul
gml
specif
peptid
observ
specif
cellular
immun
respons
count
spot
plate
fig
fig
protein
maintain
adjuvant
fulllength
also
use
peptid
sinc
asppr
protein
induc
antiself
antibodi
vaccin
mice
thu
rais
question
whether
preexist
antibodi
protein
adjuv
may
suppress
adjuvant
use
subsequ
vaccin
formul
previou
studi
shown
antibodi
induc
impact
abil
induc
immun
respons
bystand
antigen
eg
rbd
sarscov
spike
protein
commerci
influenza
viru
ha
vaccin
use
adjuv
sequenti
vaccin
moreov
shown
antiselfantibodi
elicit
three
immun
nonhuman
primat
much
reduc
thu
point
possibl
level
antiselfantibodi
could
speci
depend
present
less
issu
move
forward
develop
adjuv
notabl
anoth
protein
adjuv
flagellin
use
clinic
clinic
trial
best
knowledg
report
show
antiflagellin
antibodi
signific
impact
adjuvant
proteinbas
adjuv
fuse
protein
antigen
subunit
vaccin
consist
immunogen
adjuv
sinc
asppr
much
shorter
sequenc
believ
asppr
suitabl
fulllength
construct
express
fusion
proteinbas
subunit
vaccin
summari
demonstr
truncat
fragment
asppr
contain
domain
maintain
adjuvant
fulllength
suggest
asppr
develop
adjuv
human
use
